Treatment outcomes and prognostic factors in children with hepatoblastoma using a risk-stratified approach.
India
alpha-fetoprotein
hepatoblastoma
liver transplantation
survival
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
revised:
24
01
2023
received:
18
12
2022
accepted:
24
02
2023
medline:
25
5
2023
pubmed:
14
4
2023
entrez:
13
4
2023
Statut:
ppublish
Résumé
Not all the significant progress made in the management of children with hepatoblastoma (HB) has translated into improved outcomes in limited-resource settings. There are limited data on outcomes in children with HB from India. All patients diagnosed with HB between July 2013 and December 2020 were risk-stratified and treated as per International Liver Tumor Strategy Group (SIOPEL). Patients with standard-risk HB received cisplatin monotherapy and those with high-risk HB received alternating cycles of cisplatin and the combination of carboplatin plus doxorubicin. Data regarding demographic details, chemotherapy, surgery, liver transplantation, outcomes, prognostic factors, and toxicity were collected. Of 157 patients with HB, 117 (74%) were high risk, 31 (20%) were standard risk, and nine (6%) unknown. Patients with standard-risk disease had excellent outcomes, with 3-year event-free survival (EFS) and overall survival (OS) of 96% and 100%, respectively. Among high-risk HB, six underwent orthotopic liver transplantation of which four were alive at last follow-up. The 3-year EFS and OS of patients with high-risk disease was 56% and 66%, respectively. Outcomes of patients with PRETEXT IV (3-year EFS: 42%, 3-year OS: 50%) and metastatic disease (3-year EFS: 30%, 3-year OS: 50%) were dismal. Patients with serum alpha-fetoprotein (AFP) reduction greater than 90% following two courses of chemotherapy had favorable outcomes; 3-year EFS: 80% versus 58% (p = .013) and 3-year OS: 95% vs. 68% (p < .01). Only two (6%) of 31 patients with relapse/refractory HB were alive at a median follow-up of 36 months, and both had received salvage chemotherapy and surgery. While children with standard-risk HB had excellent outcomes, those with high-risk disease continue to do poorly. Serial monitoring of serum AFP values is a cost-effective and reliable predictor of outcomes. Orthotopic liver transplantation remains a viable option for inoperable disease in resource-limited settings as well.
Sections du résumé
BACKGROUND
Not all the significant progress made in the management of children with hepatoblastoma (HB) has translated into improved outcomes in limited-resource settings. There are limited data on outcomes in children with HB from India.
METHODS
All patients diagnosed with HB between July 2013 and December 2020 were risk-stratified and treated as per International Liver Tumor Strategy Group (SIOPEL). Patients with standard-risk HB received cisplatin monotherapy and those with high-risk HB received alternating cycles of cisplatin and the combination of carboplatin plus doxorubicin. Data regarding demographic details, chemotherapy, surgery, liver transplantation, outcomes, prognostic factors, and toxicity were collected.
RESULTS
Of 157 patients with HB, 117 (74%) were high risk, 31 (20%) were standard risk, and nine (6%) unknown. Patients with standard-risk disease had excellent outcomes, with 3-year event-free survival (EFS) and overall survival (OS) of 96% and 100%, respectively. Among high-risk HB, six underwent orthotopic liver transplantation of which four were alive at last follow-up. The 3-year EFS and OS of patients with high-risk disease was 56% and 66%, respectively. Outcomes of patients with PRETEXT IV (3-year EFS: 42%, 3-year OS: 50%) and metastatic disease (3-year EFS: 30%, 3-year OS: 50%) were dismal. Patients with serum alpha-fetoprotein (AFP) reduction greater than 90% following two courses of chemotherapy had favorable outcomes; 3-year EFS: 80% versus 58% (p = .013) and 3-year OS: 95% vs. 68% (p < .01). Only two (6%) of 31 patients with relapse/refractory HB were alive at a median follow-up of 36 months, and both had received salvage chemotherapy and surgery.
CONCLUSIONS
While children with standard-risk HB had excellent outcomes, those with high-risk disease continue to do poorly. Serial monitoring of serum AFP values is a cost-effective and reliable predictor of outcomes. Orthotopic liver transplantation remains a viable option for inoperable disease in resource-limited settings as well.
Substances chimiques
Cisplatin
Q20Q21Q62J
alpha-Fetoproteins
0
Carboplatin
BG3F62OND5
Doxorubicin
80168379AG
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e30302Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Czauderna P, Haeberle B, Hiyama E, et al. The Children's Hepatic tumors International Collaboration (CHIC): novel global rare tumor database yields new prognostic factors in hepatoblastoma and becomes a research model. Eur J Cancer. 2016;52:92-101. http://www.ejcancer.com/article/S0959804915008692/fulltext
Katzenstein HM, Langham MR, Malogolowkin MH, et al. Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children's Oncology Group, multicentre, phase 3 trial. Lancet Oncol. 2019;20(5):719-727. https://pubmed.ncbi.nlm.nih.gov/30975630/
Perilongo G, Maibach R, Shafford E, et al. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med. 2009;361(17):1662-1670. https://pubmed.ncbi.nlm.nih.gov/19846851/
Zsiros J, Brugieres L, Brock P, et al. Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study. Lancet Oncol. 2013;14(9):834-842. https://pubmed.ncbi.nlm.nih.gov/23831416/
Magrath I, Steliarova-Foucher E, Epelman S, et al. Paediatric cancer in low-income and middle-income countries. Lancet Oncol. 2013;14(3):e104-e116. https://pubmed.ncbi.nlm.nih.gov/23434340/
Agarwala S, Gupta A, Bansal D, et al. Management of hepatoblastoma: ICMR consensus document. Indian J Pediatr. 2017;84(6):456-464. https://pubmed.ncbi.nlm.nih.gov/28353129/
Arora RS. Outcomes of hepatoblastoma in the Indian context. Indian Pediatr. 2012;49(4):307-309. https://pubmed.ncbi.nlm.nih.gov/22080621/
Manuprasad A, Radhakrishnan V, Sunil BJ, et al. Hepatoblastoma: 16-years’ experience from a tertiary cancer centre in India. Pediatr Hematol Oncol J. 2018;3(1):13-16.
Rammohan A, Rela M, Kumar GV, et al. Outcomes for high-risk hepatoblastoma in a resource-challenged setting. BJS Open. 2020;4(4):630-636. https://academic.oup.com/bjsopen/article/4/4/630/6135891
Czauderna P, Otte JB, Aronson DC, et al. Guidelines for surgical treatment of hepatoblastoma in the modern era-recommendations from the Childhood Liver Tumour Strategy Group of the International Society of Paediatric Oncology (SIOPEL). Eur J Cancer. 2005;41(7):1031-1036. https://pubmed.ncbi.nlm.nih.gov/15862752/
Aronson DC, Schnater JM, Staalman CR, et al. Predictive value of the pretreatment extent of disease system in hepatoblastoma: results from the International Society of Pediatric Oncology Liver Tumor Study Group SIOPEL-1 study. J Clin Oncol. 2005;23(6):1245-1252. https://pubmed.ncbi.nlm.nih.gov/15718322/
Pritchard J, Brown J, Shafford E, et al. Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approach-results of the first prospective study of the International Society of Pediatric Oncology. J Clin Oncol. 2000;18(22):3819-3828. https://pubmed.ncbi.nlm.nih.gov/11078495/
Zsíros J, Maibach R, Shafford E, et al. Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study. J Clin Oncol. 2010;28(15):2584-2590. https://pubmed.ncbi.nlm.nih.gov/20406943/
Qureshi SS, Kembhavi SA, Kazi M, et al. Feasibility of nonanatomical liver resection in diligently selected patients with hepatoblastoma and comparison of outcomes with anatomic resection. Eur J Pediatr Surg. 2021;31(3):236-244. http://www.thieme-connect.com/products/ejournals/html/10.1055/s-0040-1710328
Qureshi SS, Bhagat M, Kembhavi S, Vora T, Ramadwar M, Talole S. PRETEXT II-III multifocal hepatoblastoma: significance of resection of satellite lesions irrespective of their disappearance after chemotherapy. Pediatr Surg Int. 2015;31(6):573-579. https://pubmed.ncbi.nlm.nih.gov/25904441/
Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-612. https://pubmed.ncbi.nlm.nih.gov/19414839/
Huang J, Hu Y, Jiang H, et al. CHIC risk stratification system for predicting the survival of children with hepatoblastoma: data from children with hepatoblastoma in China. Front Oncol. 2020;10:2559
Abdelahamid S, Khedr RA, El Wakeel M, et al. Hepatoblastoma in developing countries; eight years of single centre experience. J Cancer Ther. 2018;09(10):793-806.
Dall'Igna P, Brugieres L, Christin AS, et al. Hepatoblastoma in children aged less than six months at diagnosis: a report from the SIOPEL group. Pediatr Blood Cancer. 2018;65(1):e26791. https://onlinelibrary.wiley.com/doi/full/10.1002/pbc.26791
Nguyen R, McCarville MB, Sykes A, et al. Rapid decrease of serum alpha-fetoprotein and tumor volume predicts outcome in children with hepatoblastoma treated with neoadjuvant chemotherapy. Int J Clin Oncol. 2018;23(5):900-907. https://pubmed.ncbi.nlm.nih.gov/29744604/
Van Tornout JM, Buckley JD, Quinn JJ, et al. Timing and magnitude of decline in alpha-fetoprotein levels in treated children with unresectable or metastatic hepatoblastoma are predictors of outcome: a report from the Children's Cancer Group. J Clin Oncol. 1997;15(3):1190-1197. https://pubmed.ncbi.nlm.nih.gov/9060563/
Lovvorn HN, Ayers D, Zhao Z, et al. Defining hepatoblastoma responsiveness to induction therapy as measured by tumor volume and serum alpha-fetoprotein kinetics. J Pediatr Surg. 2010;45(1):121-129. https://pubmed.ncbi.nlm.nih.gov/20105591/
Koh KN, Park M, Kim BE, et al. Prognostic implications of serum alpha-fetoprotein response during treatment of hepatoblastoma. Pediatr Blood Cancer. 2011;57(4):554-560. https://onlinelibrary.wiley.com/doi/full/10.1002/pbc.23069
Qureshi SS, Bhagat M, Kembhavi S, Vora T, Ramadwar M, Talole S. PRETEXT II-III multifocal hepatoblastoma: significance of resection of satellite lesions irrespective of their disappearance after chemotherapy. Pediatr Surg Int. 2015;31(6):573-579. https://link.springer.com/article/10.1007/s00383-015-3713-0
Katzenstein HM, Furman WL, Malogolowkin MH, et al. Vincristine/irinotecan upfront window treatment of high-risk hepatoblastoma: a report from the Children's Oncology Group (COG) AHEP0731 study committee. Cancer. 2017;123(12):2360
Venkatramani R, Wang L, Malvar J, et al. Tumor necrosis predicts survival following neo-adjuvant chemotherapy for hepatoblastoma. Pediatr Blood Cancer. 2012;59(3):493-498. https://onlinelibrary.wiley.com/doi/full/10.1002/pbc.24038
Wang LL, Filippi RZ, Zurakowski D, et al. Effects of neoadjuvant chemotherapy on hepatoblastoma: a morphologic and immunohistochemical study. Am J Surg Pathol. 2010;34(3):287-299. https://pubmed.ncbi.nlm.nih.gov/20118773/
Trobaugh-Lotrario A, Katzenstein HM, Ranganathan S, et al. Small cell undifferentiated histology does not adversely affect outcome in hepatoblastoma: a report from the Children's Oncology Group (COG) AHEP0731 Study Committee. J Clin Oncol. 2022;40(5):459-467.
Heifetz SA, French M, Correa M, Grosfeld JL. Hepatoblastoma: the Indiana experience with preoperative chemotherapy for inoperable tumors; clinicopathological considerations. Pediatr Pathol Lab Med. 2010;17(6):857-874. https://www.tandfonline.com/doi/abs/10.1080/15513819709168750
Shukla PJ, Barreto SG, Qureshi SS, et al. Hepatoblastoma: a single institutional experience of 18 cases. Pediatr Surg Int. 2008;24(7):799-802. https://pubmed.ncbi.nlm.nih.gov/18458915/
Kazi M, Qureshi S. Upper transversal hepatectomy for pediatric liver tumors based on the inferior right hepatic vein. J Indian Assoc Pediatr Surg. 2021;26(6):404. https://pubmed.ncbi.nlm.nih.gov/34912137/
Rela M, Shanmugham NP. Accessible pediatric liver transplantation in India: a long way to go. Indian Pediatr. 2017;54(11):911-912. https://pubmed.ncbi.nlm.nih.gov/29217801/
Nagral S, Nanavati A, Nagral A. Liver transplantation in India: at the crossroads. J Clin Exp Hepatol. 2015;5(4):329-340. https://pubmed.ncbi.nlm.nih.gov/26900275/
Lim IIP, Bondoc AJ, Geller JI, Tiao GM. Hepatoblastoma-the evolution of biology, surgery, and transplantation. Children (Basel). 2018;6(1):1. https://doi.org/10.3390/children6010001
Semeraro M, Branchereau S, Maibach R, et al. Relapses in hepatoblastoma patients: clinical characteristics and outcome-experience of the International Childhood Liver Tumour Strategy Group (SIOPEL). Eur J Cancer. 2013;49(4):915-922. https://pubmed.ncbi.nlm.nih.gov/23146961/
Huang D-S, Sci AM, Zhang W-L, et al. Clinical characteristics and outcome of 55 cases of hepatoblastoma relapses. Arch Med Sci. 2021. https://www.archivesofmedicalscience.com/pdf-132445-64127?filename=Clinical%20characteristics.pdf
Trobaugh-Lotrario AD, Feusner JH. Relapsed hepatoblastoma. Pediatr Blood Cancer. 2012;59(5):813-817. https://onlinelibrary.wiley.com/doi/full/10.1002/pbc.24218